OR WAIT null SECS
April 02, 2024
Innovation in this space depends on strategizing for GMP compliance and market access.
March 29, 2024
J&J’s nipocalimab is in development for reducing the risk of FNAIT in alloimmunized pregnant adults, a rare disease that may risk the life of the fetus or newborn.
March 15, 2024
ProBioGen and Mapp Biopharmaceutical will use the former’s GlymaxX technology to develop a cell line for an afucosylated antibody that targets Marburg virus infection
March 06, 2024
Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
January 02, 2024
The success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
December 19, 2023
Bristol Myers Squibb and SystImmune plan to co-develop and co-commercialize lead ADC candidate for cancer treatment in US.
October 11, 2023
Roche will gain exclusive worldwide rights to develop, manufacture, and commercialize Ionis’ investigational RNA-based therapeutic candidates for Alzheimer's and Huntington's disease.
New routes to cancer treatment can be found with the help of tumor-infiltrating lymphocyte (TIL) therapies.
September 21, 2023
A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy.